
SNYR Stock Forecast & Price Target
SNYR Analyst Ratings
Bulls say
Synergy CHC is facing short-term challenges due to weak Q1 results and the cancellation of a distribution deal in the Middle East, but the long-term potential for growth remains strong. With the FOCUSfactor brand showing significant growth and the company's strong position in the large brain health and energy RTD industries, there are multiple catalysts for potential growth. Despite current challenges, the company's recent long-term financial performance has been solid, and its undervalued stock presents a potential investment opportunity for those willing to bear the risks and uncertainties.
Bears say
Synergy CHC is facing significant financial challenges, as evidenced by its declining revenue and negative earnings in its latest quarter. With a substantial amount of debt and limited cash reserves, the company's financial position is precarious. Despite an attractive valuation, the risks associated with the company could outweigh the potential upside. The lack of Q4 guidance and weak Q1 results further demonstrate the uncertainties surrounding the company, and the lack of visibility on its future performance. Overall, there are concerns about the company's ability to turn around its financials and drive positive growth, making it a risky investment choice at this time.
This aggregate rating is based on analysts' research of Synergy CHC Corp and is not a guaranteed prediction by Public.com or investment advice.
SNYR Analyst Forecast & Price Prediction
Start investing in SNYR
Order type
Buy in
Order amount
Est. shares
0 shares